JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Journal of Neurology, Neurosurgery, and Psychiatry 2008;79:490; doi:10.1136/jnnp.2007.135350
Copyright © 2008 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Jackson, M. J
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jackson, M. J
Related Collections
Right arrowRelated Article

EDITORIAL COMMENTARIES

Should we accept the status quo? Time for new trials in status epilepticus

Margaret J Jackson

Correspondence to:
Dr M J Jackson, Department of Neurology, Royal Victoria Infirmary, Queen Victoria Rd, Newcastle upon Tyne NE1 4LP, UK; margaret.jackson@ncl.ac.uk

The first 150 words of the full text of this article appear below.

Status epilepticus (SE), defined as a seizure or series of seizures without recovery between lasting more than 30 min, takes a variety of forms, as illustrated in the report by Knake and colleagues1 in this issue of J Neurol Neurosurg Psychiatry (see page 588). In their paper, the response to intravenous levetiracetam of 16 patients with a total of 18 episodes of status epilepticus is described. The patients were all adults; the majority of episodes of SE were complex partial and symptomatic in aetiology, a case mix that might well be seen in an acute medical admissions unit. The duration of SE is not given, a pity particularly for the patients with convulsive SE where outcome is related to duration of seizure activity. All patients received intravenous benzodiazepine, usually lorazepam, before levetiracetam. Intravenous levetiracetam was given as a bolus dose of 250–1500 mg and was associated with seizure . . . [Full text of this article]


Related Article

Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus
S Knake, J Gruener, K Hattemer, K M Klein, S Bauer, W H Oertel, H M Hamer, and F Rosenow
J. Neurol. Neurosurg. Psychiatry 2008 79: 588-589. [Abstract] [Full Text] [PDF]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd.